Drug
Ferric Carboxymaltose
Ferric Carboxymaltose: highest development phase Post-Market, developed by Hikma, United Therapeutics, Viatris and others. 8 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Hikma, United Therapeutics, Viatris
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ferric carboxymaltose NCT03759964 | Post-Market | Anemia, Iron Deficiency |
| Ferric carboxymaltose NCT01913808 | Post-Market | Postoperative Anemia |
| ferric carboxymaltose NCT01245777 | Post-Market | Restless Leg Syndrome |
| FERRIC CARBOXYMALTOSE | Approved | |
| ferric carboxymaltose NCT01513369 | Phase 3 | Type 2 Diabetes Mellitus |
| Ferric carboxymaltose NCT03769441 | Phase 3 | Iron-deficiency |
| Ferric carboxymaltose NCT03591406 | Phase 3 | Iron Deficiency Anemia |
| Ferric carboxymaltose (FCM) NCT04246021 | Not Applicable | Anemia |
Latest
Follow Ferric Carboxymaltose on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.